Inventia company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

inventiaid.com

Founded Year

2012

Stage

Acquired | Acquired

Total Raised

$850K

About Inventia

Inventia is a provider of Digital Onboarding, Video Biometric Recognition and Video Collaboration services using software technology Phygital 4X. Inventia combines Artificial Intelligence, Video Engagement, Remote Collaboration, Identity Recognition, Biometrics and Digital Signature, creating a 'Phygital' (physical + digital) experience which helps companies increase online conversion rates, enabling the sale of products and services that today present limitations of a regulatory nature or of elevated complexity.On February 11th, 2020, Inventia was acquired by CRIF, terms of the agreement were not disclosed.

Inventia Headquarter Location

Via Antonio Fontanesi, 4

Milan, 20146,

Italy

+39-0236-696490

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Inventia

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Inventia in 1 CB Insights research brief, most recently on Feb 14, 2020.

Expert Collections containing Inventia

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Inventia is included in 1 Expert Collection, including Artificial Intelligence.

A

Artificial Intelligence

8,717 items

This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.

Inventia Patents

Inventia has filed 8 patents.

The 3 most popular patent topics include:

  • Authentication methods
  • Computer memory
  • Diabetes
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/3/2018

9/21/2021

Authentication methods, Password authentication, Cryptographic protocols, Computer network security, Identity management

Grant

Application Date

4/3/2018

Grant Date

9/21/2021

Title

Related Topics

Authentication methods, Password authentication, Cryptographic protocols, Computer network security, Identity management

Status

Grant

Latest Inventia News

Inventia sells $30mn worth of American Depositary Shares

Sep 23, 2021

September 23, 2021 PARIS, FRANCE: Inventiva, a clinical-stage biopharmaceutical company, has completed sales of 2.083 million American Depositary Shares (ADS) pursuant to the company’s ATM program established on August 2, 2021, through Jefferies LLC. Each American Depositary Shares (ADS) represents one ordinary share of the company. In the ATM sales, an aggregate of 2,083,334 new American Depositary Shares (ADS) and the same number of underlying new ordinary shares have been issued to existing and new specialized institutional investors through a capital increase at a price of $14.40 per new ADS, without a discount to the volume weighted average price of the company’s ADS over the last trading day and representing a discount of 3% to the volume weighted average price of the company’s ordinary shares on the regulated market of Euronext in Paris over the last trading day. The new shares will represent 5.1% of the share capital of the company upon completion of the transaction. It is anticipated that the settlement and delivery of the new shares will take place on September 27, 2021. They will be admitted to trading on Euronext and the issued ADSs will trade on Nasdaq. Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of NASH, MPS and other diseases with significant unmet medical need. The Company has a scientific team of approximately 70 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, as well as in clinical development. It also owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly‑owned research and development facility. Inventiva is a public company listed on compartment C of the regulated market of Euronext Paris and on the Nasdaq Global Market in the United States. www.inventivapharma.com

  • When was Inventia founded?

    Inventia was founded in 2012.

  • Where is Inventia's headquarters?

    Inventia's headquarters is located at Via Antonio Fontanesi, 4, Milan.

  • What is Inventia's latest funding round?

    Inventia's latest funding round is Acquired.

  • How much did Inventia raise?

    Inventia raised a total of $850K.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.